Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
368 articles
A bibliometric analysis of 595 papers maps how glymphatic-Alzheimer's research has grown exponentially, pinpointing AQP4, sleep, and DTI-ALPS imaging as the hottest frontiers.
Cerebral hypoperfusion drives glymphatic dysfunction in systemic inflammation — and restoring blood flow with levosimendan reverses it.
A completed RCT tests whether treating insomnia with CBT-I can improve cognition and slow amyloid buildup in adults aged 60–85.
Boosting BNIP3 in muscle tissue extends fly lifespan and shields the brain from age-related degeneration via a muscle-brain signaling axis.
A major review reveals how the glymphatic system's failure drives neurodegeneration and brain tumor resistance — and how to fix it.
Blocking brain lymphatic drainage triggers age-dependent compensatory responses — young rats adapt, middle-aged rats largely cannot, with proteomic signs of neurodegeneration in both.
New mouse study reveals how the brain's waste-clearance system modulates toxic protein buildup linked to Parkinson's disease.
PET-MRI study of 54 cSVD patients links microglial activation to enlarged white matter perivascular spaces, not BBB leakage.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
A completed Canadian platform trial enrolls 354 at-risk adults in a multidomain online brain health program targeting dementia prevention.
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
A new study warns that diabetes medications could confound Alzheimer's biomarker studies, distorting our understanding of the diabetes-dementia link.
